|
GDNF-Mimetic Self-Assembling Supramolecular Nanostructure to Enhance Survival and Function of Dopaminergic Neurons for Treatment of Parkinson's Disease
NU 2024-175
SHORT DESCRIPTION
A self-assembling bioactive matrix that presents GDNF-mimetic peptides to support the viability, maturation, and function of dopaminergic neurons in cell replacement therapy for treatment of Parkinson’s Disease.
INVENTORS
Samuel Stupp*
Weinberg College of Arts and Sciences, Department...
Published: 5/11/2026
|
Updated: 4/30/2026
|
Inventor(s):
Keywords(s): Biologic, Biomaterials, Cell delivery, CNS - Central Nervous System, CVA - Cerebrovascular Accident, Nanomaterials, Neurodegenerative disease, Neurologic disease, Neurology, PD - Parkinson's Disease, Scaffold, SCI - Spinal cord injury, TBI - Traumatic brain injury, Therapeutics
Category(s): Life Sciences > Therapeutics, Life Sciences > Biomarkers & Biomedical Research Tools, Life Sciences > Healthcare Devices, Tools & IT > Neurology
|
|
STING Agonist 8803 for Blood-Brain Barrier Opening in Glioblastoma Treatment
SHORT DESCRIPTION
Chemical compound that opens the blood-brain barrier to enhance delivery of therapeutics for treating glioblastoma.
INVENTORS
Amy Heimberger*
Northwestern University Feinberg School of Medicine, Department of Neurological Surgery
* Principal Investigator
NU Tech ID: NU 2025-212
IP...
Published: 5/7/2026
|
Updated: 4/27/2026
|
Inventor(s):
Keywords(s): AD - Alzheimer’s Disease, Adjunct therapy, ALS - Amyotrophic Lateral Sclerosis, Animal Model, Autoimmune disease, Bladder cancer, Brain cancer, Breast cancer, Cancer Treatment, Cancer/Oncology, Cervical cancer, CNS - Central Nervous System, Colon cancer, Drug delivery, Endometrial cancer, Gastric cancer, GBM - Glioblastoma, Head and neck cancer, Immunology, Immunotherapy, Liver cancer, Lung cancer, MS - Multiple Sclerosis, Neurodegenerative disease, Neurologic disease, Ovarian cancer, Pancreatic cancer, PD - Parkinson's Disease, Prostate cancer, Repurposed Drugs, Research tool, Small molecule, Targeted therapy, TBI - Traumatic brain injury, Therapeutics
Category(s): Life Sciences > Therapeutics, Life Sciences > Biomarkers & Biomedical Research Tools
|
|
Biomolecular Condensates as Protein Degradation Tools for Intracellular Targets
SHORT DESCRIPTION
A targeted-protein degradation platform for intracellular targets, addressing resistant oncogenic and neurodegenerative targets.
INVENTORS
Shana Kelley*
Weinberg College of Arts & Sciences, Department of Chemistry
Yi Li
* Principal Investigator
NU Tech ID: NU 2025-050
IP...
Published: 5/7/2026
|
Updated: 4/27/2026
|
Inventor(s):
Keywords(s): AD - Alzheimer’s Disease, Biologic, Biomolecular condensates, Cancer/Oncology, Drug delivery, Nanoparticle, Neurodegenerative disease, Neurologic disease, Neurology, PD - Parkinson's Disease, Platform technology, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics, Life Sciences > Biomarkers & Biomedical Research Tools
|
|
Methods to Treat Neurodegenerative Disorders by Reducing Nuclear Aggregates and Modulating Adenosine‑to‑Inosine RNA Editing
SHORT DESCRIPTION
Novel disease‑modifying approach that dissolves toxic nuclear RNA–protein aggregates and restores synaptic function in neurodegenerative diseases by inhibiting adenosine‑to‑inosine (A‑to‑I) RNA editing and modulating ADAR enzymes.
INVENTORS
Joseph Mazzulli*
Northwestern University Feinberg School...
Published: 5/13/2026
|
Updated: 4/27/2026
|
Inventor(s):
Keywords(s): Lewy bodies, Neurodegenerative disease, Neurology, PD - Parkinson's Disease, RNA - Ribonucleic Acid, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
2-(Pyridin-3-yl)quinazoline compounds as glucocerebrosidase modulators
✅ Feedback form for Tech ID 2015-064
PROPOSED TITLE: 2-(Pyridin-3-yl) quinazoline Compounds as Glucocerebrosidase Modulators
NU 2015-064
INVENTORS
Richard Silverman*
Dimitri Krainc
Jianbin Zheng
SHORT DESCRIPTION
Novel substituted quinazoline compounds that modulate glucocerebrosidase activity, offering a promising therapeutic approach for...
Published: 11/18/2025
|
Updated: 11/18/2025
|
Inventor(s):
Keywords(s): Neurodegenerative disease, Neurologic disease, PD - Parkinson's Disease, Research tool, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Potent and selective Cav1.3 negative allosteric modulators for use in Parkinson's Disease
NU 2010-105 and NU 2024-179
INVENTORS
Richard Silverman* (Northwestern University, Weinberg College of Arts & Science, Department of Chemistry)
Dalton Surmeier Jr.* (Northwestern University, Feinberg School of Medicine, Chair of the Department of Neuroscience)
Garry Cooper
Soosung Kang
Jack Nguyen
SHORT DESCRIPTION
For pharmaceutical...
Published: 5/21/2026
|
Updated: 11/7/2025
|
Inventor(s):
Keywords(s): Neurodegenerative disease, Neurologic disease, Neurology, PD - Parkinson's Disease
Category(s): Life Sciences > Therapeutics
|
|
TauSeeK: Disease Specific Tau Protein Fibrils & Seeding Proteins
NU 2024-154
INVENTORS
Songi Han*
Austin Dubose
Michael Vigers
Andrew Longhini
Vishnu Vijayan
Kenneth Kosik
Samuel Lobo
Peter C. Ryffel
Lokeswara Rao Potnuru
Karen Tsay
Chung-Ta Han
SHORT DESCRIPTION
Compositions, kits, and methods for generating synthetic miniature tau peptides and fibrils, and synthetic full-length pathogenic tau...
Published: 3/23/2026
|
Updated: 10/30/2025
|
Inventor(s):
Keywords(s): AD - Alzheimer’s Disease, Drug discovery, Drug screening, HD - Huntington's Disease, Neurodegenerative disease, Neurology, PD - Parkinson's Disease, Research tool
Category(s): Life Sciences > Biomarkers & Biomedical Research Tools
|
|
A Novel Combination Therapy for Parkinson’s Disease
NU 2013-149
INVENTORS
Dalton Surmeier Jr. (Northwestern University, Feinberg School of Medicine, Chair of the Department of Neuroscience)*
Daniel Galtieri
Ema Ilijic
Enrico Zampese
Jaime Guzman-Lucero
Javier Sanchez
SHORT DESCRIPTION
This technology uses a low-dose combination of two FDA-approved compounds to reduce oxidative stress in neurons...
Published: 11/6/2025
|
Updated: 10/9/2025
|
Inventor(s):
Keywords(s): Biomedical, Drug delivery, Neurodegenerative disease, Neurologic disease, PD - Parkinson's Disease, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Cell-type specific disruption of M1 muscarinic acetylcholine receptor expression to alleviate Parkinson's disease
NU 2024-244
INVENTORS
Dalton J. Surmeier Jr*
Tatiana Tkatch
Shenyu Zhai
SHORT DESCRIPTION
Gene therapy targeting M1 muscarinic receptor expression in striatal spiny projection neurons to enhance levodopa response and slow Parkinson’s Disease progression.
BACKGROUND
Parkinson’s Disease (PD) is the second most common age-related...
Published: 1/5/2026
|
Updated: 3/27/2025
|
Inventor(s):
Keywords(s): CNS - Central Nervous System, Gene therapy, Neurodegenerative disease, Neurologic disease, Neurology, PD - Parkinson's Disease, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Gene therapy for levodopa-induced dyskinesia
NU 2024-086
INVENTORS
Dalton J. Surmeier Jr*
Weixing Shen
Shenyu Zhai
Tatiana Tkatch
Qiaoling Cui
Zhong Xie
SHORT DESCRIPTION
Gene therapy targeting GRIN2B in striatal spiny projection neurons to treat levodopa-induced dyskinesia.
BACKGROUND
Parkinson’s Disease (PD) is the second most common age-related neurodegenerative disease...
Published: 1/5/2026
|
Updated: 3/27/2025
|
Inventor(s):
Keywords(s): CNS - Central Nervous System, Dyskinesis, Neurodegenerative disease, Neurologic disease, Neurology, PD - Parkinson's Disease, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|